416 related articles for article (PubMed ID: 35199161)
1. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F
Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161
[TBL] [Abstract][Full Text] [Related]
2. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review.
Nelson SM; Davis SR; Kalantaridou S; Lumsden MA; Panay N; Anderson RA
Hum Reprod Update; 2023 May; 29(3):327-346. PubMed ID: 36651193
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review.
Drechsel KCE; Pilon MCF; Stoutjesdijk F; Meivis S; Schoonmade LJ; Wallace WHB; van Dulmen-den Broeder E; Beishuizen A; Kaspers GJL; Broer SL; Veening MA
Hum Reprod Update; 2023 Jul; 29(4):486-517. PubMed ID: 36779325
[TBL] [Abstract][Full Text] [Related]
5. The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.
Anderson RA; Su HI
Front Endocrinol (Lausanne); 2020; 11():574263. PubMed ID: 33117288
[TBL] [Abstract][Full Text] [Related]
6. Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women.
Dunlop CE; Anderson RA
Maturitas; 2015 Mar; 80(3):245-50. PubMed ID: 25596814
[TBL] [Abstract][Full Text] [Related]
7. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments.
Silva C; Ribeiro Rama AC; Reis Soares S; Moura-Ramos M; Almeida-Santos T
J Ovarian Res; 2019 Oct; 12(1):102. PubMed ID: 31672154
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Anti-Mullerian Hormone Levels Pre- and Post-Hematopoietic Cell Transplantation in Pediatric and Adolescent Females with Sickle Cell Disease.
George SA; Lai KW; Lewis RW; Bryson EW; Haight AE; Meacham LR
Transplant Cell Ther; 2022 Nov; 28(11):770.e1-770.e6. PubMed ID: 35995392
[TBL] [Abstract][Full Text] [Related]
9. Female adolescents and young women previously treated for pediatric malignancies: assessment of ovarian reserve and gonadotoxicity risk stratification for early identification of patients at increased infertility risk.
Parissone F; Di Paola R; Balter R; Garzon S; Zaffagnini S; Neri M; Vitale V; Tridello G; Cesaro S
J Pediatr Endocrinol Metab; 2021 Jan; 34(1):25-33. PubMed ID: 33068384
[TBL] [Abstract][Full Text] [Related]
10. Does an association exist between menstrual cycle length within the normal range and ovarian reserve biomarkers during the reproductive years? A systematic review and meta-analysis.
Younis JS; Iskander R; Fauser BCJM; Izhaki I
Hum Reprod Update; 2020 Nov; 26(6):904-928. PubMed ID: 32514566
[TBL] [Abstract][Full Text] [Related]
11. AMH assessment five or more years after an initially low AMH level.
Desongnis S; Robin G; Dewailly D; Pigny P; Catteau-Jonard S
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():70-74. PubMed ID: 33171420
[TBL] [Abstract][Full Text] [Related]
12. The Evaluation of Ovarian Function Recovery Following Treatment of Primary Ovarian Insufficiency: A Systematic Review.
Kuang X; Tang Y; Xu H; Ji M; Lai D
Front Endocrinol (Lausanne); 2022; 13():855992. PubMed ID: 35573993
[TBL] [Abstract][Full Text] [Related]
13. Premature ovarian insufficiency and early depletion of the ovarian reserve in the monogenic Mulibrey nanism disorder.
Karlberg S; Tiitinen A; Alfthan H; Lipsanen-Nyman M
Hum Reprod; 2018 Jul; 33(7):1254-1261. PubMed ID: 29860321
[TBL] [Abstract][Full Text] [Related]
14. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study.
Brougham MF; Crofton PM; Johnson EJ; Evans N; Anderson RA; Wallace WH
J Clin Endocrinol Metab; 2012 Jun; 97(6):2059-67. PubMed ID: 22472563
[TBL] [Abstract][Full Text] [Related]
15. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T; Barrière P; Masson D
Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
[TBL] [Abstract][Full Text] [Related]
16. Ovarian Reserve Markers in Premature Ovarian Insufficiency: Within Different Clinical Stages and Different Etiologies.
Jiao X; Meng T; Zhai Y; Zhao L; Luo W; Liu P; Qin Y
Front Endocrinol (Lausanne); 2021; 12():601752. PubMed ID: 33815272
[TBL] [Abstract][Full Text] [Related]
17. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.
Visser JA; Schipper I; Laven JS; Themmen AP
Nat Rev Endocrinol; 2012 Jan; 8(6):331-41. PubMed ID: 22231848
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
Chen H; Xiao L; Li J; Cui L; Huang W
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
[TBL] [Abstract][Full Text] [Related]
19. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
[TBL] [Abstract][Full Text] [Related]
20. Impact of unilateral versus bilateral ovarian endometriotic cystectomy on ovarian reserve: a systematic review and meta-analysis.
Younis JS; Shapso N; Fleming R; Ben-Shlomo I; Izhaki I
Hum Reprod Update; 2019 May; 25(3):375-391. PubMed ID: 30715359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
